Table 2 Collected series of clinical trials to mitigate liver IRI
From: Molecular Mediators of Liver Ischemia and Reperfusion Injury: A Brief Review
Reference | Study type | n | Model | Treatment | Outcome |
|---|---|---|---|---|---|
Lang et al. (106) reduced | Single-center prospective RCT | 10 | OLT | Inhaled NO, perioperative | Improved recovery; decreased LOS, liver cell apoptosis |
Baskin-Bey et al. (107) | Multicenter prospective RCT | 23–27 | OLT | Pan-caspase inhibitor (IDN-6556), during cold storage/flush and IV after OLT | Reduced early liver cell apoptosis |
Aldrighetti et al. (108) | Single-center prospective RCT | 36 | Liver resection; intermittent WI | Methylprednisolone, preoperative | Reduced IRI |
Bogetti et al. (113) | Single-center prospective RCT | 12 | OLT | Thymoglobulin, intraoperative and postoperative | Reduced IRI and improved function |
St Peter et al. (110) | Single-center prospective RCT | 10 | OLT | Tacrolimus in allograft flush | Improved early graft function and decreased injury |
Kim et al. (122) | Single-center prospective RCT | 16–25 | Liver resection; continuous WI | Protease inhibitor (gabexate mesilate); preoperative or intraoperative | Reduced IRI with preoperative treatment |